Teva and Blackstone Reach $400 Million Strategic Funding Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BX?
Source: NASDAQ.COM
- Strategic Funding Agreement: Teva Pharmaceuticals has entered into a $400 million strategic funding agreement with Blackstone Life Sciences, with funds allocated over four years to support the clinical development of duvakitug, reflecting confidence in the drug's potential.
- Clinical Development Support: Blackstone Life Sciences will finance ongoing and future development costs for duvakitug, and upon FDA approval, Teva will pay milestone payments to Blackstone, further advancing the product's path to market.
- Market Potential: Duvakitug is a human monoclonal antibody targeting TL1A, currently in phase 3 clinical studies for ulcerative colitis and Crohn's disease, and successful commercialization could meet the urgent market demand for new therapies.
- Collaborative Development: Teva is co-developing duvakitug with Sanofi under a separate agreement, and subject to regulatory approval, will co-commercialize the asset, enhancing market competitiveness and expanding market share.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BX
Wall Street analysts forecast BX stock price to rise
12 Analyst Rating
5 Buy
7 Hold
0 Sell
Moderate Buy
Current: 115.330
Low
166.00
Averages
176.60
High
205.00
Current: 115.330
Low
166.00
Averages
176.60
High
205.00
About BX
Blackstone Inc. is an alternative asset manager. Its asset management includes global investment strategies focused on real estate, private equity, infrastructure, life sciences, growth equity, credit, real assets, secondaries, and hedge funds. Its Real Estate segment comprises its management of opportunistic real estate funds, Core+ real estate funds, and real estate debt strategies. Its Private Equity segment includes its management of flagship Corporate Private Equity funds, sector and geographically focused Corporate Private Equity funds, core private equity funds, an investment platform, and others. Its Credit & Insurance segment consists of Blackstone Credit & Insurance, which is organized into three overarching strategies: private corporate credit, liquid corporate credit and infrastructure and asset-based credit. Its Multi-Asset Investing segment is organized into four investment platforms: Absolute Return, Multi-Strategy, Total Portfolio Management, and Public Real Assets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Blackstone's $4B Investment Deal with New World Stalls
- Investment Deal Stalled: Blackstone's proposed $4 billion investment in New World Development has stalled due to control disputes, with Blackstone initially planning to invest approximately $2.5 billion into a special-purpose vehicle to become New World's largest shareholder.
- Family Control Issues: The Cheng family, which effectively controls New World through a 45% stake in Chow Tai Fook Enterprises, is resisting relinquishing control, even as they consider investing between $1 billion and $1.5 billion to address the company's high debt-to-equity ratio and rental obligations.
- Market Challenges: New World faces ongoing earnings losses and restructuring needs amid Hong Kong's tough property market, with the family exploring alternative investors or asset sales that would allow them to maintain control.
- Stock Performance: Despite these challenges, New World Development's stock price has climbed about 26% this year, indicating some market confidence in its future potential.
See More
Senior Plc Receives Takeover Proposal from U.S. Firms
- Increased Acquisition Interest: British aerospace components maker Senior Plc announced on Tuesday that it received a preliminary takeover approach from U.S. investment firms Tinicum and Blackstone, indicating a growing interest that could drive further increases in its market value.
- Market Valuation Overview: As of Tuesday, Senior's market value stood at approximately £1.25 billion (around $1.66 billion), providing potential acquirers with a clear financial backdrop that may attract more investors to participate in the bidding process.
- Earnings Exceed Expectations: Senior's recent report of annual profits exceeding market expectations, driven by strong demand and improved pricing in its aerospace division, lays a solid foundation for attracting acquisition interest.
- Competitive Bidding Landscape: In addition to Tinicum and Blackstone, private equity group Advent has also confirmed its interest in Senior, reflecting a heightened acquisition enthusiasm in the market that could lead to competitive bidding increases.
See More
Teva and Blackstone Reach $400 Million Strategic Funding Agreement
- Strategic Funding Agreement: Teva Pharmaceuticals has entered into a $400 million strategic funding agreement with Blackstone Life Sciences, with funds allocated over four years to support the clinical development of duvakitug, reflecting confidence in the drug's potential.
- Clinical Development Support: Blackstone Life Sciences will finance ongoing and future development costs for duvakitug, and upon FDA approval, Teva will pay milestone payments to Blackstone, further advancing the product's path to market.
- Market Potential: Duvakitug is a human monoclonal antibody targeting TL1A, currently in phase 3 clinical studies for ulcerative colitis and Crohn's disease, and successful commercialization could meet the urgent market demand for new therapies.
- Collaborative Development: Teva is co-developing duvakitug with Sanofi under a separate agreement, and subject to regulatory approval, will co-commercialize the asset, enhancing market competitiveness and expanding market share.
See More
Blue Owl Capital Shares Drop Amid Liquidity Concerns
- Liquidity Pressure Intensifies: Blue Owl Capital's shares fell 3.89% to $10.27 as concerns over liquidity strains and redemption pressures heightened, leaving investors uneasy about future capital-raising prospects.
- Surge in Trading Volume: The company saw a trading volume of 54 million shares, which is 141% above its three-month average of 22.4 million shares, indicating heightened market scrutiny regarding its liquidity issues that could impact investor confidence.
- Asset Sale Developments: Blue Owl agreed to sell approximately $1.4 billion in direct lending investments at 99.7% of par, suggesting that loan values remain close to face value, despite increased scrutiny on non-bank lenders that may affect future fundraising capabilities.
- Employee Stock Ownership Plan: The company filed a shelf registration for an employee stock ownership plan covering up to 50 million Class A shares, with investors closely watching for potential dilution effects, especially amid rising redemption pressures.
See More
Blue Owl Capital Faces Liquidity Pressures
- Stock Decline: Blue Owl Capital (NYSE:OWL) closed at $10.27 on Tuesday, down 3.89%, as fresh reports of liquidity strains and redemption pressures raised investor concerns, with shares hitting a 52-week low of $10.07, reflecting market caution towards private credit.
- Surge in Trading Volume: The company saw trading volume reach 54 million shares, approximately 141% above its three-month average of 22.4 million shares, indicating heightened market focus on its liquidity issues, with investors closely watching how asset sales and fund gating risks will impact future capital raising.
- Asset Sale Developments: Blue Owl agreed to sell about $1.4 billion in direct lending investments at 99.7% of par, suggesting loan values remain close to face value; however, scrutiny of non-bank lenders intensified following reports of $1.7 billion in net outflows from Blackstone's BCRED vehicle.
- Employee Stock Ownership Plan: The company filed a shelf registration for an employee stock ownership plan covering up to 50 million Class A shares, raising investor concerns about potential dilution, especially as ongoing redemption pressures persist, making future fundraising efforts critical to balance these challenges.
See More
Trump Orders Maritime Trade Insurance in Gulf
- Policy Response: Trump announced on social media that he has directed the U.S. Development Finance Corporation to provide political risk insurance and financial guarantees for all maritime trade transiting the Strait of Hormuz, aiming to alleviate concerns over energy supply disruptions, which could stabilize market sentiment.
- Market Recovery: Following Trump's statement, the S&P 500 trimmed its midday loss from 1.5% to 0.6%, indicating a positive investor reaction to the policy support, which may help restore market confidence.
- Sector Impact: Royal Caribbean Group and other cruise operators saw significant rebounds after Trump's announcement, suggesting that fears of the Iran conflict impacting consumer travel spending may be easing, potentially boosting travel-related expenditures.
- Future Outlook: Trump's mention of more actions to come was interpreted by the market as ongoing support for energy markets, with investors keenly watching whether normal traffic through the Strait of Hormuz can resume and if the Navy escort threat can expedite a diplomatic resolution.
See More
Blackstone's $4B Investment Deal with New World Stalls
- Investment Deal Stalled: Blackstone's proposed $4 billion investment in New World Development has stalled due to control disputes, with Blackstone initially planning to invest approximately $2.5 billion into a special-purpose vehicle to become New World's largest shareholder.
- Family Control Issues: The Cheng family, which effectively controls New World through a 45% stake in Chow Tai Fook Enterprises, is resisting relinquishing control, even as they consider investing between $1 billion and $1.5 billion to address the company's high debt-to-equity ratio and rental obligations.
- Market Challenges: New World faces ongoing earnings losses and restructuring needs amid Hong Kong's tough property market, with the family exploring alternative investors or asset sales that would allow them to maintain control.
- Stock Performance: Despite these challenges, New World Development's stock price has climbed about 26% this year, indicating some market confidence in its future potential.
See More
Senior Plc Receives Takeover Proposal from U.S. Firms
- Increased Acquisition Interest: British aerospace components maker Senior Plc announced on Tuesday that it received a preliminary takeover approach from U.S. investment firms Tinicum and Blackstone, indicating a growing interest that could drive further increases in its market value.
- Market Valuation Overview: As of Tuesday, Senior's market value stood at approximately £1.25 billion (around $1.66 billion), providing potential acquirers with a clear financial backdrop that may attract more investors to participate in the bidding process.
- Earnings Exceed Expectations: Senior's recent report of annual profits exceeding market expectations, driven by strong demand and improved pricing in its aerospace division, lays a solid foundation for attracting acquisition interest.
- Competitive Bidding Landscape: In addition to Tinicum and Blackstone, private equity group Advent has also confirmed its interest in Senior, reflecting a heightened acquisition enthusiasm in the market that could lead to competitive bidding increases.
See More
Teva and Blackstone Reach $400 Million Strategic Funding Agreement
- Strategic Funding Agreement: Teva Pharmaceuticals has entered into a $400 million strategic funding agreement with Blackstone Life Sciences, with funds allocated over four years to support the clinical development of duvakitug, reflecting confidence in the drug's potential.
- Clinical Development Support: Blackstone Life Sciences will finance ongoing and future development costs for duvakitug, and upon FDA approval, Teva will pay milestone payments to Blackstone, further advancing the product's path to market.
- Market Potential: Duvakitug is a human monoclonal antibody targeting TL1A, currently in phase 3 clinical studies for ulcerative colitis and Crohn's disease, and successful commercialization could meet the urgent market demand for new therapies.
- Collaborative Development: Teva is co-developing duvakitug with Sanofi under a separate agreement, and subject to regulatory approval, will co-commercialize the asset, enhancing market competitiveness and expanding market share.
See More
Blue Owl Capital Shares Drop Amid Liquidity Concerns
- Liquidity Pressure Intensifies: Blue Owl Capital's shares fell 3.89% to $10.27 as concerns over liquidity strains and redemption pressures heightened, leaving investors uneasy about future capital-raising prospects.
- Surge in Trading Volume: The company saw a trading volume of 54 million shares, which is 141% above its three-month average of 22.4 million shares, indicating heightened market scrutiny regarding its liquidity issues that could impact investor confidence.
- Asset Sale Developments: Blue Owl agreed to sell approximately $1.4 billion in direct lending investments at 99.7% of par, suggesting that loan values remain close to face value, despite increased scrutiny on non-bank lenders that may affect future fundraising capabilities.
- Employee Stock Ownership Plan: The company filed a shelf registration for an employee stock ownership plan covering up to 50 million Class A shares, with investors closely watching for potential dilution effects, especially amid rising redemption pressures.
See More
Blue Owl Capital Faces Liquidity Pressures
- Stock Decline: Blue Owl Capital (NYSE:OWL) closed at $10.27 on Tuesday, down 3.89%, as fresh reports of liquidity strains and redemption pressures raised investor concerns, with shares hitting a 52-week low of $10.07, reflecting market caution towards private credit.
- Surge in Trading Volume: The company saw trading volume reach 54 million shares, approximately 141% above its three-month average of 22.4 million shares, indicating heightened market focus on its liquidity issues, with investors closely watching how asset sales and fund gating risks will impact future capital raising.
- Asset Sale Developments: Blue Owl agreed to sell about $1.4 billion in direct lending investments at 99.7% of par, suggesting loan values remain close to face value; however, scrutiny of non-bank lenders intensified following reports of $1.7 billion in net outflows from Blackstone's BCRED vehicle.
- Employee Stock Ownership Plan: The company filed a shelf registration for an employee stock ownership plan covering up to 50 million Class A shares, raising investor concerns about potential dilution, especially as ongoing redemption pressures persist, making future fundraising efforts critical to balance these challenges.
See More
Trump Orders Maritime Trade Insurance in Gulf
- Policy Response: Trump announced on social media that he has directed the U.S. Development Finance Corporation to provide political risk insurance and financial guarantees for all maritime trade transiting the Strait of Hormuz, aiming to alleviate concerns over energy supply disruptions, which could stabilize market sentiment.
- Market Recovery: Following Trump's statement, the S&P 500 trimmed its midday loss from 1.5% to 0.6%, indicating a positive investor reaction to the policy support, which may help restore market confidence.
- Sector Impact: Royal Caribbean Group and other cruise operators saw significant rebounds after Trump's announcement, suggesting that fears of the Iran conflict impacting consumer travel spending may be easing, potentially boosting travel-related expenditures.
- Future Outlook: Trump's mention of more actions to come was interpreted by the market as ongoing support for energy markets, with investors keenly watching whether normal traffic through the Strait of Hormuz can resume and if the Navy escort threat can expedite a diplomatic resolution.
See More
